ArticleMolecules (Basel, Switzerland)2022
Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- "Edible plant-associated fungal endophytes as sources of bioactive specialized metabolites: antimicrobial and docking insights".Archives of microbiology · 2026Article
- Novel seleno-ureido hybrids targeting head and neck cancer and beyond: design, synthesis, and apoptosis-mediated anticancer evaluation.RSC advances · 2026Article
- Article
- Design, synthesis, and anticancer evaluation of novel pyrazole-thiophene hybrid derivatives as multitarget inhibitors of wild EGFR, mutant (T790M) EGFR, and VEGFR-2.RSC advances · 2025Article
- In Vitro and In Silico Evaluation of the Potential Anti-Prostate Cancer Activity ofInternational journal of molecular sciences · 2025Article
- Design, spectroscopic characterizations, and biological investigation of oxospiro[chromine-4,3-indolene]-based compounds as promising antiproliferative EGFR inhibitors and antimicrobial agents.Molecular diversity · 2025Article
- Guanidine dicycloamine-based analogs: green chemistry synthesis, biological investigation, and molecular docking studies as promising antibacterial and antiglycation leads.Molecular diversity · 2024Article
- MMP-9 expression in rat pup incisor teeth is not altered by maternal hypertension or maternal atenolol treatment during pregnancy and lactation.Journal of molecular histology · 2024Article
- Design and evaluation of sulfadiazine derivatives as potent dual inhibitors of EGFRRSC advances · 2024Article
- Bioinformatics analysis of signature genes related to cell death in keratoconus.Scientific reports · 2024Article
- Exploring the sedative properties of natural molecules from hop cones (Frontiers in chemistry · 2024Article
- Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Relationship between Trace Elements and Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in Medullary Thyroid Carcinoma.Biological trace element research · 2023Article
- Chemical and Biological Review of Endophytic Fungi Associated withMolecules (Basel, Switzerland) · 2023Review
- Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach.PloS one · 2023Article
- Thieno[2,3-ACS omega · 2022Article
- Ligand-based design, synthesis, computational insights, andJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Spectroscopic, Thermodynamic and Molecular Docking Studies on Molecular Mechanisms of Drug Binding to Proteins.Molecules (Basel, Switzerland) · 2022Article
- Design, synthesis and molecular docking of new fused 1Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis,Journal of enzyme inhibition and medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Keratoconus (KC) is a serious disease that can affect people of any race or nationality, although the exact etiology and pathogenic mechanism are still unknown. In this study, thirty-two FDA-approved ophthalmic drugs were exposed to virtual screening using docking studies against both the MMP-2 and MMP-9 proteins to find the most promising inhibitors as a proposed computational mechanism to treat keratoconus. Matrix metalloproteinases (MMPs) are zinc-dependent proteases, and MMP inhibitors (MMPIs) are usually designed to interact with zinc ion in the catalytic (CAT) domain, thus interfering with enzymatic activity. In our research work, the FDA-approved ophthalmic medications will be investigated as MMPIs, to explore if they can be repurposed for KC treatment. The obtained findings of the docking study suggest that atenolol and ampicillin are able to accommodate into the active sites of MMP-2 and MMP-9. Additionally, both exhibited binding modes similar to inhibitors used as references, with an ability to bind to the zinc of the CAT. Molecular dynamic simulations and the MM-GBSA binding free-energy calculations revealed their stable binding over the course of 50 ns. An additional pharmacophoric study was carried out on MMP-9 (PDB ID: 1GKC) using the co-crystallized ligand as a reference for the future design and screening of the MMP-9 inhibitors. These promising results open the door to further biological research to confirm such theoretical results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.